Pitolisant
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Pitolisant: From Narcolepsy to Insomnia (Disease)
One-Sentence Summary
Pitolisant is a selective histamine H3-receptor inverse agonist originally developed and approved (per literature evidence) for narcolepsy with or without cataplexy, where it works by promoting wakefulness. The TxGNN model predicts it may be effective for Insomnia (disease), but the only directly designed clinical trial was withdrawn with zero enrollment, and the drug’s known wake-promoting mechanism runs opposite to what insomnia treatment requires. Evidence for this specific prediction is weak (1 withdrawn trial, 8 indirect publications, none an insomnia RCT) — this should be treated as a low-confidence, mechanistically questionable signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Narcolepsy (with or without cataplexy) — inferred from literature evidence in this pack; Taiwan license/original_indications data unavailable |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L4 |
| US Market Status | Not Marketed (未上市) in Taiwan |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data from DrugBank is not available (flagged as a High-severity data gap, DG002). Based on the mechanistic information available in this evidence pack, Pitolisant is a selective histamine H3-receptor inverse agonist/antagonist. It works by blocking presynaptic H3 autoreceptors, which increases histamine release and enhances wakefulness — this is precisely the mechanism used to treat excessive daytime sleepiness in narcolepsy and OSA-related residual sleepiness (as reflected in the literature evidence for this drug).
This creates a fundamental mechanistic concern for the “insomnia” prediction: insomnia treatment requires promoting sleep/sedation, while Pitolisant pharmacologically does the opposite — it promotes arousal. The evidence pack’s own rationale explicitly flags this as a likely false positive, probably arising from proximity of “sleep disorder” nodes in the knowledge graph rather than a genuine pharmacological fit. Supporting this concern, the only clinical trial directly designed around a sleep/behavioral endpoint for Pitolisant beyond narcolepsy/OSA (NCT02800083, alcohol use disorder) was withdrawn with 0 patients enrolled, and none of the 8 literature citations report insomnia efficacy data — they instead describe narcolepsy, OSA/excessive daytime sleepiness (opposite direction), or general H3-receptor pharmacology reviews.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02800083 | Phase 2 | Withdrawn | 0 | Designed to evaluate Pitolisant for alcohol use disorder (heavy drinking days as primary endpoint); trial was withdrawn before enrollment began — no efficacy or safety data was generated. Relevance to insomnia graded C (indirect, no data produced). |
Note: No clinical trial in this evidence pack directly tests Pitolisant for insomnia. This is the only trial retrieved under this candidate, and it produced no usable data.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36931805 | 2023 | RCT (narcolepsy, pediatric) | The Lancet. Neurology | Phase 3 RCT confirming safety/efficacy of Pitolisant in children with narcolepsy with/without cataplexy — supports wake-promoting profile, not insomnia. |
| 33121980 | 2021 | RCT (OSA/EDS) | Chest | RCT showing Pitolisant reduces residual excessive daytime sleepiness in CPAP-adherent OSA patients — opposite therapeutic direction to insomnia. |
| 31917607 | 2020 | RCT (OSA/EDS) | Am J Respir Crit Care Med | RCT of Pitolisant for daytime sleepiness in OSA patients refusing CPAP — again a wake-promoting, not sleep-promoting, effect. |
| 36169322 | 2022 | Real-world cohort (narcolepsy) | Revista de neurología | Real-life “WAKE” study evaluating effectiveness/safety of Pitolisant in treatment-refractory type 1 narcolepsy patients. |
| 34225942 | 2021 | Review | Handbook of Clinical Neurology | Overview of histamine receptor pharmacology (H1–H4) in health and disease; general mechanistic background only. |
| 30214155 | 2018 | Review | Drug Design, Development and Therapy | Review of Pitolisant’s development and therapeutic role in narcolepsy management. |
| 34521328 | 2022 | Review | Current Neuropharmacology | Reviews histaminergic system changes in neuropsychiatric disorders; mentions Pitolisant for narcolepsy alongside doxepin (H1 antagonist) for insomnia — highlighting these are pharmacologically distinct approaches. |
| 22356925 | 2012 | Review | Clinical Neuropharmacology | Early review describing Pitolisant as a stimulant alternative for narcolepsy-cataplexy in adolescents. |
Summary: None of the 8 publications report insomnia efficacy data. The evidence base for this indication is entirely composed of narcolepsy/OSA studies (opposite pharmacological direction) and general H3-receptor mechanism reviews.
US Market Information
Pitolisant currently holds 0 approved licenses in Taiwan (market status: 未上市 / Not Marketed). No license records are available in this evidence pack to summarize approved indications or dosage forms.
Safety Considerations
Please refer to the package insert for safety information. Detailed TFDA warnings, contraindications, and drug-drug interaction data were not available in this evidence pack (flagged as a Blocking data gap, DG001) — this data must be obtained before any safety evaluation (S1 stage) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The predicted mechanism directly contradicts the therapeutic need for insomnia (Pitolisant is wake-promoting, not sedating), and the only trial designed around this candidate’s evidence trail was withdrawn with zero patients. No clinical or literature evidence supports efficacy for insomnia; this prediction is best treated as a likely knowledge-graph artifact rather than a genuine repurposing signal.
To proceed, the following is needed:
- TFDA/FDA package insert data (warnings, contraindications, DDI) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action from DrugBank (DG002) to formally validate the mechanistic mismatch noted above
- If pursued at all, a properly designed and completed insomnia-specific trial, since none currently exists
- Consider deprioritizing this candidate in favor of other TxGNN signals in this pack with stronger mechanistic plausibility (e.g., ADHD, rank 2 — H3-antagonism as a cognitive/attention enhancer — though this remains at “Research Question” stage with no clinical trial evidence either)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.